WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical firm targeted on the event of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the therapy of sufferers with most cancers, at present introduced that the Company will take part within the Cell Therapy Corporate Panel Discussion on the TD Cowen 44^th Annual Health Care Conference being held on the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.

A webcast of the panel dialogue might be obtainable on the “Events and Presentations” part of the Company’s web site at ir.tscan.com. An archived replay of the webcast might be obtainable on the Company’s web site for 30 days following the occasion.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical firm targeted on the event of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the therapy of sufferers with most cancers. The Company’s lead TCR-T remedy candidates, TSC-100 and TSC-101, are in growth for the therapy of sufferers with hematologic malignancies to eradicate residual illness and forestall relapse after allogeneic hematopoietic cell transplantation. The Company can be growing multiplexed TCR-T remedy candidates for the therapy of assorted strong tumors. The Company has developed and continues to broaden its ImmunoBank, the Company’s repository of therapeutic TCRs that acknowledge various targets and are related to a number of HLA varieties, to supply custom-made, enhanced, multiplexed TCR-T therapies for sufferers with quite a lot of cancers.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com